nach oben

Die Gastroenterologie

Erschienen in:

24.08.2022 | Dysphagie | Schwerpunkt

Sklerodermie

verfasst von: Prof. Dr. Thomas Frieling

Erschienen in: Die Gastroenterologie | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die gastrointestinale Beteiligung bei der systemischen Sklerodermie (SSc) wird klinisch durch Ösophagusfunktionsstörungen mit Dysfunktion der tubulären Peristaltik und Schwächung der gastroösophagealen Barriere mit erhöhtem Reflux und ihren Komplikationen bestimmt. Die gastrointestinale Beteiligung ist prognoserelevant und für einen signifikanten Anteil der Todesursachen verantwortlich. Die Pathophysiologie besteht aus vaskulären Veränderungen, Fibrose und Immunveränderungen, die wahrscheinlich in sequenzieller Folge ablaufen und die Speiseröhre schädigen. Beschwerden, die mit Ösophagusfunktionsstörungen korrelieren, sind Dysphagie, Reflux, Aufstoßen, Dyspepsie, Sodbrennen bzw. retrosternale Schmerzen. Zusätzlich können Gewichtsverlust, Übelkeit, Erbrechen, Husten bzw. Heiserkeit vorliegen. Die Diagnostik beinhaltet die Ösophagogastroduodenoskopie, die hochauflösende Ösophagusmanometrie und die kombinierte 24-h-pH-Metrie-Impedanzmessung. Die Therapie umfasst die Behandlung der Grunderkrankung und eine konsequente leitliniengerechte Refluxtherapie.

Li B, Yan J, Pu J, Tang J, Xu S, Wang X (2021) Esophageal dysfunction in systemic sclerosis: an update. Rheumatol Ther 8:1535–1549. https://doi.org/10.1007/s40744-021-00382-0CrossRefPubMedPubMedCentral

Kadakuntla A, Juneja A, Sattler S, Agarwal A, Panse D, Zakhary N, Pasumarthi A, Shapiro L, Tadros M (2021) Dysphagia, reflux and related sequelae due to altered physiology in scleroderma. World J Gastroenterol 27:5201–5218. https://doi.org/10.3748/wjg.v27.i31.5201CrossRefPubMedPubMedCentral

Emmanuel AJ (2016) Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol 13:461–472PubMedCrossRef

Ebert EC (2008) Esophageal disease in progressive systemic sclerosis. Curr Treat Options Gastroenterol 11:64–69PubMedCrossRef

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 72:1747–1755. https://doi.org/10.1136/annrheumdis-2013-204424CrossRefPubMed

Roberts CG, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697–1703PubMedPubMedCentralCrossRef

Miller LS, Liu JB, Klenn PJ et al (1993) Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology 105:31–39PubMedCrossRef

D’Angelo WA, Fries JF, Masi AT, Shulman LE (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46:428–440PubMedCrossRef

Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557–567PubMedPubMedCentralCrossRef

10.

Wigley FM (2009) Vascular disease in scleroderma. Clin Rev Allergy Immunol 36:150–175PubMedCrossRef

11.

Kimmel JN, Carlson DA, Hinchcliff M et al (2016) The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil 28:1157–1165PubMedPubMedCentralCrossRef

12.

Roman S, Hot A, Fabien N et al (2011) Esophageal dysmotility associated with systemic sclerosis: a highresolution manometry study. Dis Esophagus 24:299–304PubMedCrossRef

13.

Taroni JN, Martyanov V, Huang CC et al (2015) Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Res Ther 17:194PubMedPubMedCentralCrossRef

14.

Vettori S, Tolone S, Capocotta D et al (2018) Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value. Clin Rheumatol 37:1239–1247PubMedCrossRef

15.

McMahan ZH, Domsic RT, Zhu L, Medsger TA, Casciola-Rosen L, Shah AA (2019) Anti-RNPC‑3 (U11/U12) antibodies in systemic sclerosis in patients with moderate-to-severe gastrointestinal dysmotility. Neurogastroenterol Motil 71:1164–1170

16.

Gyger G, Baron M (2012) Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 14:22–29PubMedCrossRef

17.

Te’treault M‑P, Kahrilas P (2019) GI manifestations with a focus on the esophagus: recent progress in understanding pathogenesis. Curr Rheumatol Rep 21:42CrossRef

18.

Tack K, Pandolfino JE (2018) Pathophysiology of gastroesophageal reflux disease. Gastroenterology 154:277–288PubMedCrossRef

19.

Fass R, Boeckxstaens GE, El-Serag H, Rosen R, Sifrim D, Vaezi MF (2021) Gastro-oesophageal reflux disease. Nat Rev Dis Primers 7(1):55. https://doi.org/10.1038/s41572-021-00287-wCrossRefPubMed

20.

Koop H et al (2022) S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology. Z Gastroenterol (im Druck)

21.

Adarsh MB (2019) Esophageal manometry, esophagogastroduodenoscopy, and duodenal mucosal histopathology in systemic sclerosis. Rev Assoc Med Bras 3:206–209

22.

López NPY, Lugo-Zamudio G, Barbosa-Cobos RE, Wong-Lam A, Torres-López E (2017) Frequency of motor alterations detected through manometry in patients with esophageal symptoms and scleroderma. Rev Gastroenterol Mex 82:193

23.

Vischio J, Saeed F, Karimeddini M et al (2012) Progression of esophageal dysmotility in systemic sclerosis. J Rheumatol 39:986–991PubMedCrossRef

24.

Lahcene M, Oumnia N, Matougui N, Boudjella M, Touchene B (2011) Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol 2011:325826PubMedPubMedCentral

25.

Arif T, Masood Q, Singh J, Hassan I (2015) Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol 15:24PubMedPubMedCentralCrossRef

26.

Tang DM, Pathikonda M, Harrison M, Fisher RS, Friedenberg FK, Parkman HP (2013) Symptoms and esophageal motility based on phenotypic findings of scleroderma. Dis Esophagus 26:197–203PubMedCrossRef

27.

Gyawali CP, Kahrilas PJ, Savarino E et al (2018) Modern diagnosis of GERD: the Lyon Consensus. Gut 67:1351–1362PubMedCrossRef

28.

Aggarwal N, Lopez R, Gabbard S, Wadhwa N, Devaki P, Thota PN (2017) Spectrum of esophageal dysmotility in systemic sclerosis on high-resolution esophageal manometry as defined by Chicago classification. Dis Esophagus 30:1–6PubMedCrossRef

29.

Matthew W, Emma W, Dorothy L, Sandra L, Michael C (2019) White esophageal lesions in a patient with scleroderma: epidermoid metaplasia. Gastroenterol Rep 2:2

30.

Kuribayashi S (2019) Relationship between esophageal motility abnormalities and skin or lung involvements in patients with systemic sclerosis. JGH Open 54:950–962

31.

Bütikofer S, Jordan S, Sauter M et al (2019) Abnormal esophageal motility during a solid test meal in systemic sclerosis—detection even in very early disease and association with disease progression. Neurogastroenterol Motil 31:e13480PubMedCrossRef

32.

Charles SA, Nicole B, Luc L (2010) Lung atelectasis secondary to massive esophageal dilation in a patient with scleroderma. Can Respir J 17:96–98CrossRef

33.

Clarke JO, Pandolfino JE (2017) Upper gastrointestinal tract: manifestations of systemic sclerosis. In: Varga J, Denton C, Wigley F, Allanore Y, Kuwana M (Hrsg) Scleroderma. Springer, Cham, S 427–441 https://doi.org/10.1007/978-3-319-31407-5_30CrossRef

34.

Junginger T, Kneist W, Sultanov F, Eckardt VF (2002) Long-term outcome of myotomy and semi-fundoplication in achalasia. Chirurg 73(7):704–709. https://doi.org/10.1007/s00104-002-0474-9CrossRefPubMed

35.

Makuuchi H, Shimada H, Chino O, Nishi T, Tanaka H, Ohshiba G (1997) Endoscopic classification of reflux esophagitis and its new developments. Nihon Geka Gakkai Zasshi 98:926–931PubMed

36.

Asano Y, Jinnin M, Kawaguchi Y et al (2018) Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol 45:633–691PubMedCrossRef

37.

Rutka K, Garkowski A, Karaszewska K, Łebkowska U (2021) Imaging in diagnosis of systemic sclerosis. J Clin Med 10:248PubMedCentralCrossRef

38.

Yadlapati R, Kahrilas PJ, Fox MR, Bredenoord AJ, Prakash Gyawali C, Roman S, Babaei A, Mittal RK, Rommel N, Savarino E, Sifrim D, Smout A, Vaezi MF, Zerbib F, Akiyama J, Bhatia S, Bor S, Carlson DA, Chen JW, Cisternas D, Cock C, Coss-Adame E, de Bortoli N, Defilippi C, Fass R, Ghoshal UC, Gonlachanvit S, Hani A, Hebbard GS, Wook Jung K, Katz P, Katzka DA, Khan A, Kohn GP, Lazarescu A, Lengliner J, Mittal SK, Omari T, Park MI, Penagini R, Pohl D, Richter JE, Serra J, Sweis R, Tack J, Tatum RP, Tutuian R, Vela MF, Wong RK, Wu JC, Xiao Y, Pandolfino JE (2021) Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterol Motil 33:e14058. https://doi.org/10.1111/nmo.14058CrossRefPubMedPubMedCentral

39.

Keller J, Fox MR, Allescher HD, Frieling T, Fuchs KH, Goebel-Stengel M, Pehl C, Schirra J, van der Voort I, Storr M (2018) Interpretation und performance of high-resolution esophageal manometry: Recommendations of the German Association of Neurogastroenterology and Motility (DGNM) and the German Association of Gastroenterology, Digestive and Metabolic Diseases (DGVS). Z Gastroenterol 56:1378–1408. https://doi.org/10.1055/a-0713-0944CrossRefPubMed

40.

Chwiesko A, Kowal-Bielecka O, Sierakowski S (2019) Perspectives on the interlinked nature of systemic sclerosis and reflux disease. Expert Rev Gastroenterol Hepatol 13:213–227PubMedCrossRef

41.

Mainie I, Tutuian R, Patel A, Castell DO (2008) Regional esophageal dysfunction in scleroderma and achalasia using multichannel intraluminal impedance and manometry. Dig Dis Sci 53:210–216PubMedCrossRef

42.

Schutyser W, Cruyt L, Vulsteke JB, Lenaerts JL, De Langhe E (2020) The role of high-resolution manometry in the assessment of upper gastrointestinal involvement in systemic sclerosis: a systematic review. Clin Rheumatol 39:149–157PubMedCrossRef

43.

Motegi SI, Jordan S, Sauter M et al (2019) Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progression. J Gastroenterol 31:e13480

44.

Jean F, Aubert A, Bloch F et al (1986) Effects of diltiazem versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum 29:1054–1055PubMedCrossRef

45.

Assassi S, Del Junco D, Sutter K et al (2009) Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 61:1403–1411PubMedPubMedCentralCrossRef

46.

Nagaraja V, McMahan ZH, Getzug T, Khanna D (2015) Management of gastrointestinal involvement in scleroderma. Curr Treatm Opt Rheumatol 1:82–105PubMedPubMedCentralCrossRef

47.

Horikoshi T, Sekiguchi T, Kusano M, Matsuzaki T (1991) Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis. Gastroenterol Jpn 26:145–150PubMedCrossRef

48.

Tandaipan JL, Castellvi IJ (2020) Systemic sclerosis and gastrointestinal involvement. Rev Colomb Reumatol 27:44–54

49.

Miller JB, Gandhi N, Clarke J, McMahan Z (2018) Gastrointestinal involvement in systemic sclerosis: an update. J Clin Rheumatol 24:328PubMedCrossRef

50.

Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002) Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 21:43–45PubMedCrossRef

51.

Foocharoen C, Chunlertrith K, Mairiang P et al (2017) Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology 56:214–222PubMedCrossRef

52.

Ghani S, Serraj I, Salihoun M, Acharki M, Kabbaj N (2020) Esophageal motility disorders in systemic sclerosis. PAMJ Clin Med 2:108. https://doi.org/10.11604/pamj-cm.2020.2.108.21950CrossRef

53.

Sallam H, McNearney TA, Doshi D, Chen JD (2007) Transcutaneous electrical nerve stimulation (TENS) improves upper GI symptoms and balances the sympathovagal activity in scleroderma patients. Dig Dis Sci 52:1329PubMedCrossRef

54.

Andrade A, Folstein MK, Davis BR (2017) Case report of robotic dor fundoplication for scleroderma esophagus with aperistalsis on manometry. Int J Surg Case Rep 37:69–71PubMedPubMedCentralCrossRef

55.

Yan J, Strong AT, Sharma G et al (2018) Surgical management of gastroesophageal reflux disease in patients with systemic sclerosis. Surg Endosc 32:3855–3860PubMedCrossRef

56.

Chatterjee A, Chaudhury S (2013) A rare case of interaorticobronchial diverticulum of esophagus in a case of scleroderma. Lung India 30:222PubMedPubMedCentralCrossRef

Titel: Sklerodermie
verfasst von: Prof. Dr. Thomas Frieling
Publikationsdatum: 24.08.2022
Verlag: Springer Medizin
Schlagwörter: Dysphagie
Motilitätsstörungen
Gastroösophageale Refluxkrankheit
Systemische Sklerodermie
Dysphagie
Sklerodermie
Motilitätsstörungen
Endoskopie
Ösophagogastroduodenoskopie
Dysphagie
Erschienen in: Die Gastroenterologie / Ausgabe 5/2022
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI: https://doi.org/10.1007/s11377-022-00646-3

Magen-Darm-Erkrankungen in der Hausarztpraxis

Häufige gastrointestinale Krankheiten in der niedergelassenen Praxis sind Thema in diesem aufgezeichneten MMW-Webinar. Welche Differenzialdiagnosen bei Oberbauchbeschwerden sollten Sie kennen? Wie gelingt eine erfolgreiche probiotische Behandlung bei Reizdarm? Welche neuen Entwicklungen und praktischen Aspekte gibt es bei Diagnostik und Behandlung der chronisch entzündlichen Darmerkrankungen?

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Mitteilungen des BDI

Mitteilungen der GARPS

Sarkoidose

Mitteilungen des Netzwerks gegen Darmkrebs

Mitteilungen der Gesellschaft für Gastroenterologie in NRW

Update: Vaskulitiden im Grenzbereich von Leber- und Darmerkrankungen

Magen-Darm-Erkrankungen in der Hausarztpraxis